DUBLIN, Jan. 31, 2019 /PRNewswire/ --
The "Large Volume Wearable Injectors Market (4th Edition), 2018-2030" report has been added to ResearchAndMarkets.com's offering.
The report features an extensive study of the current market landscape and the likely future evolution of self-injection devices, over the next twelve years. It specifically lays emphasis on the emergence of patient-centric, convenient, cost-effective and user-friendly wearable drug delivery solutions that are capable of administering large volumes of a drug subcutaneously, in the home-care setting.
One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities for large volume wearable injectors. Based on parameters, such as the number of commercialized devices, number of devices under development, the price of the device and the annual adoption rate, we have provided an informed estimate on the likely evolution of the market over the period 2018-2030.
The report also features sales forecasts for the overall large volume wearable injectors market with a detailed market segmentation on the therapeutic area, geographical distribution of the market (North America / Europe / Asia Pacific / RoW), type of device (patch pump / injector and infusion pump / injector) and usability (reusable / disposable). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios namely the conservative, base, and optimistic scenarios, which represent different tracks of the industry's evolution.
Amongst other elements, the report includes:
- A detailed review of the overall landscape of the large volume wearable injectors market, highlighting the contributions of industry players related to the delivery of both insulin and non-insulin drugs, along with key device specifications. It features information on current development status of various products (under development and commercialized), type of device (patch pump / injector and infusion pump / injector), type of dose administered (continuous and bolus), route of administration (subcutaneous and others), usability (disposable and reusable), mechanism of action (driving force), mode of injection (needle, needle / cannula and needle / catheter), maximum volume of the device and availability of connected mobile application.
- A comprehensive product competitiveness analysis of all large volume wearable injectors that we came across, taking into consideration the supplier power (based on the year of establishment) and product specifications, such as type of device, type of dose, maximum volume of the device, usability, allowed route of administration, connectivity with the mobile application and availability of an integrated continuous glucose monitoring / blood glucose monitoring (CGM / BGM) system in case of insulin devices.
- Elaborate profiles of prominent product developers engaged in this domain, featuring a brief overview of the company, its financial information (if available), information on its product portfolio, recent developments and a comprehensive future outlook. Additionally, the report includes tabulated profiles of wearable drug-device combination products.
- An in-depth analysis of the various patents that have been submitted/filed related to large volume wearable injectors, since 1984. It also highlights the key parameters associated with the patents, including information on the patent type, patent offices, CPC classification, emerging areas (in terms of a number of patents filed/granted) and leading industry players (in terms of the size of intellectual property portfolio).
- A social media analysis depicting prevalent and emerging trends, and the popularity of large volume wearable injectors, as observed on the social media platform, Twitter. The analysis was based on tweets posted on the platform from 2013 to 2018 (till September).
- A comprehensive clinical trial analysis of completed, ongoing and planned studies of various large-volume wearable injector products. For the purpose of this analysis, we considered the clinical studies that started in 2010, and analyzed them on the basis of various parameters, such as trial start year, current trail status, current trial phase, study design, targeted therapeutic area, study focus and clinical outcomes.
- A case study on the role of contract manufacturing organizations in the overall manufacturing process/supply chain of wearable injectors. It includes short descriptions of the manufacturing services provided by contract service providers in the making of various device components (primary containers), infusion sets, adhesives, closures, and injection moldings.
- A list of marketed drugs / therapies and pipeline candidates that are likely to be developed in combination with large volume wearable injectors in the near future, based on an in-depth analysis of potential candidates, taking into consideration multiple parameters, such as stage of development, dosage, dose concentration, route of administration, type of dose and drug sales (in case of marketed drugs).
Key Topics Covered:
1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. Executive Summary
3. Introduction
3.1. Chapter Overview
3.2. An Overview of Drug Delivery Devices
3.3. Conventional Parenteral Delivery
3.3.1 Needlestick Injuries
3.3.1.1. Incidence and Cost Burden
3.3.1.2. Prevention of Needlestick Injuries
3.3.1.3. Government Legislations for the Prevention of Needlestick Injuries
3.4. Emergence of Self-Administration Devices
3.4.1. Driving Factors
3.4.1.1. Rising Burden of Chronic Diseases
3.4.1.2. Healthcare Cost Savings
3.4.1.3. Need for Immediate Treatment in Emergency Situations
3.4.1.4. Growing Injectable Drugs Market
3.4.1.5. Rising Focus on Patient Centricity
3.4.1.6. Need for Improving Medication Adherence
3.5. Available Self-Injection Devices
3.5.1. Prefilled Syringes
3.5.2. Pen-Injectors
3.5.3. Autoinjectors
3.5.4. Needle-Free Injectors
3.5.5. Large Volume Wearable Injectors
3.6. Regulatory Considerations
3.6.1. Medical Devices
3.6.2. Drug Device Combinations
3.7. Future Perspectives
4. Large Volume Wearable Injectors: Current Market Landscape
4.1. Chapter Overview
4.2. Large Volume Wearable Injectors: Overall Market Landscape
4.2.1. Large Volume Wearable Injectors for Non-Insulin Drugs: Market Landscape
4.2.2. Large Volume Drug Device Combinations: Market Landscape
4.2.3. Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis of Developers (Devices and Drug Device Combinations)
4.2.4. Large Volume Wearable Injectors for Insulin: Market Landscape
4.2.5. Large Volume Wearable Injectors for Insulin: Analysis of Developers
5. Product Competitiveness Analysis
5.1. Chapter Overview
5.2. Methodology
5.3. Product Competitiveness Analysis
5.3.1. Large Volume Wearable Injectors for Non-Insulin Drugs
5.3.2. Large Volume Drug Device Combinations
5.3.3. Large Volume Wearable Injectors for Insulin
6. Large Volume Wearable Injectors: Key Players
6.1. Chapter Overview
6.2. Large Volume Wearable Injectors for Non-Insulin Drugs: Key Players
6.2.1. Becton Dickinson
6.2.2. Bespak
6.2.3. Insulet
6.2.4. Medtronic
6.2.5. Roche
6.2.6. Sonceboz
6.2.7. Enable Injections
6.2.8. Sensile Medical
6.2.9. SteadyMed Therapeutics
6.2.10. West Pharmaceutical Services
6.2.11. Weibel CDS
6.3.1. CellNovo
6.3.2. CeQur
6.3.3. Debiotech
6.3.4. Eli Lilly
6.3.5. PharmaSens
6.3.6. SOOIL
6.3.7. Tandem Diabetes Care
7. Drug-Device Combinations: Tabulated Profiles
7.1. Chapter Overview
7.2. Apomorphine / ND0701
7.3. Bupivacaine / SMT-301
7.4. Ceftriaxone / sc2Wear Infusor
7.5. Furosemide / sc2Wear Infusor
7.6. Herceptin / Single Use Injector
7.7. Ketorolac / SMT-201
7.8. Levadopa and Carbidopa / ND0612 and ND0901
7.9. Neulasta / Omnipod
7.10. Repatha / Pushtronex System
7.11. Treprostinil / Trevyent
8. Patent Analysis
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Large Volume Wearable Injectors: Patent Analysis
8.3.1. Analysis by Publication Year
8.3.2. Analysis by Patent Offices Involved
8.3.3. Analysis by CPC Classification
8.3.4. Emerging Areas
8.3.5. Leading Players Based on Number of Patents
8.4. Large Volume Wearable Injectors: Patent Benchmarking Analysis
8.4.1. Analysis by Patent Characteristics
8.4.2. Analysis by Geography
8.5. Large Volume Wearable Injectors: Patent Valuation Analysis
9. Emerging Trends On Social Media
9.1. Chapter Overview
9.2. Large Volume Wearable Injectors: Trends on Twitter
9.2.1. Historical Trend in Volume of Tweets
9.2.2. Trending Words / Phrases Related to Large Volume Wearable Injectors
9.2.3. Most Influential Authors
9.2.4. Popular Players on Twitter
9.2.4.1. Roche (Accu-Chek Solo Micropump System)
9.2.4.2. Cellnovo (Cellnovo Insulin Pump)
9.2.4.3. Insulet (Omnipod)
9.2.4.4. Medtronic (Minimed Wearable Injectors)
9.2.4.5. Comparison of Popular Players Based on Number of Tweets
9.3. Concluding Remarks
10. Clinical Trial Analysis
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Large Volume Wearable Injectors: Clinical Trial Analysis
11. Case Study: Role of CMOS in Device Development Supply Chain
11.1. Chapter Overview
11.2. Device Development Supply Chain
11.3. Significance of CMOs in the Drug Delivery Device Development Process
11.4. List of Contract Manufacturing Organizations
11.4.1. Contract Manufacturers: Geographical Distribution and Services Offered
12. Large Volume Wearable Injectors: Likely Drug Candidates
12.1. Chapter Overview
12.2. Marketed Drugs
12.2.1. Most Likely Candidates for Delivery via Large Volume Wearable Injectors
12.2.2. Likely Candidates for Delivery via Large Volume Wearable Injectors
12.2.3. Less Likely Candidates for Delivery via Large Volume Wearable Injectors
12.2.4. Unlikely Candidates for Delivery via Large Volume Wearable Injectors
12.3. Clinical Drug Candidates
12.3.1. Biologics
12.3.2. Small Molecules
13. Market Sizing and Opportunity Analysis
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
14. Future Growth Opportunities
14.1. Chapter Overview
14.2. SWOT Analysis
14.2.1. Strengths
14.2.2. Weaknesses
14.2.3. Opportunities
14.2.4. Threats
14.3. Future Growth Opportunities
15. Executive Insights: Interview Transcripts & Company Snapshot
15.1. Chapter Overview
15.2. Elcam Medical
15.3. Enable Injections
15.4. Medipacs
15.5. Ratio Drug Delivery
15.6. scPharmaceuticals
15.7. Sorrel Medical
15.8. Subcuject
15.9. West Pharmaceutical Services
Companies Mentioned
- 3M
- Abbott
- AbbVie
- AbGenomics
- Ablynx
- Acceleron Pharma
- Actavis Pharma
- ADC Therapeutics
- Adrenomed
- Aduro BioTech
- Advaxis
- Aeglea BioTherapeutics
- Affibody
- Affimed
- Agenus
- AgonOx
- Akesobio Australia
- Alder BioPharmaceuticals
- Alector
- Alexion Pharmaceuticals
- Alkahest
- Alkermes
- Allakos
- Allergan
- Allozyne
- Alnylam Pharmaceuticals
- AlphaCore Pharma
- Altor BioScience
- Ambrx
- amcure
- Amgen
- Amicus Therapeutics
- Amphivena Therapeutics
- Amplyx Pharmaceuticals
- Amylin Pharmaceuticals
- Angiochem
- Animas
- Antares Pharma
- Antaros Medical
- Aprea Therapeutics
- Aptevo Therapeutics
- argenx
- Argos Therapeutics
- ArmaGen
- ARMO BioSciences
- Aronora
- Asklepion Pharmaceuticals
- Astellas Pharma
- AstraZeneca
- Atridia
- AVEO Pharmaceuticals
- Axon Neuroscience
- Bang & Olufsen Medicom
- Baril
- Basilea Pharmaceutica
- Battelle
- Baxter International
- Bayer
- Bayhill Therapeutics
- Becton Dickinson
- BeiGene
- Beijing Dongfang Biotech
- Bespak
- Bio-Path Holdings
- Bio-Thera Solutions
- BioArctic
- BIOCAD
- bioCSL
- Biogen
- BioIntegrator
- Bioject Medical Technologies
- BioMarin Pharmaceutical
- Bioniz Therapeutics
- BioNTech
- Biotest Pharmaceuticals
- Boehringer Ingelheim
- Boston Pharmaceuticals
- Bristol Myers Squibb
- Calando Pharmaceuticals
- Calibra Medical
- CANbridge Life Sciences
- Cancer Advances
- Cara Therapeutics
- Catalyst Biosciences
- CEL-SCI
- Celgene
- Celldex Therapeutics
- Cellnovo
- CeQur
- Chimerix
- CHO Pharma
- Chugai Pharmaceutical
- Cidara Therapeutics
- Cleveland BioLabs
- Conjupro Biotherapeutics
- ContraFect
- Cour Pharmaceutical Development
- CSL Behring
- CSPC Pharmaceutical Group
- CStone Pharmaceuticals
- CureTech
- CytoDyn
- Daikyo Seiko
- Datwyler
- Debiotech
- DEKA
- Dekkun
- Delta-Fly Pharma
- Dendreon
- Dexcom
- DiaMedica Therapeutics
- Diamyd Medical
- E3D Elcam Drug Delivery Devices
- EG-GILERO
- Eisai
- Eli Lilly
- Elusys Therapeutics
- EMD Serono
- Emergent BioSolutions
- Enable Injections
- Endo Pharmaceuticals
- Endocyte
- EnGeneIC
- EOFlow
- EpicentRx
- Eternity Healthcare
- European Pharma Group
- F2G
- Fabrico
- FibroGen
- Finox Biotech
- Five Prime Therapeutics
- Flex Pharma
- Flowonix Medical
- Galaxy Biotech
- Galena Biopharma
- Genentech
- GENERON
- GeneScience Pharmaceuticals
- Genexine
- Genzyme
- Gerresheimer
- Gilead Sciences
- GlaxoSmithKline
- Glenmark Pharmaceuticals
- Gliknik
- Guangzhou Cellprotek Pharmaceutical
- HAL Allergy
- Halozyme Therapeutics
- Hanmi Pharmaceutical
- Haselmeier
- Helsinn Healthcare
- Hemispherx Biopharm
- Hoffmann-La Roche
- Huabo Biopharm
- ImClone Systems
- Immatics Biotechnologies
- Immune Response BioPharma
- ImmuneMed
- ImmunGene
- Immunocore
- ImmunoFrontier
- ImmunoGen
- Immunomedics
- Immunotope
- Immunovaccine
- Implicit Bioscience
- Incuron
- Incyte
- Injex Pharma
- Innate Pharma
- Innovent Biologics
- Inovio Pharmaceuticals
- Insulet
- iNtRON Biotechnology
- IO Biotech
- Ionis Pharmaceuticals
- Ipsen
- ISU ABXIS
- Janssen
- Jerini
- JHL Biotech
- Jiangsu Hengrui Medicine
- Jiangsu T-Mab Biopharma
- Johnson & Johnson
- Jounce Therapeutics
- kaleo
- KaloBios Pharmaceuticals
- Kiniksa Pharmaceuticals
- Kissei Pharmaceutical
- Kura Oncology
- Kyowa Hakko Kirin
- Labrys Biologics
- Leadiant Biosciences
- LEO Pharma
- Levicept
- Life Science Pharmaceuticals
- MabVax Therapeutics
- MacroGenics
- Medical International Technology
- MedImmune
- Medipacs
- MedPro Safety Products
- Medtronic
- Medtrum Technologies
- Menarini Group
- Merck
- Merck Sharp & Dohme
- Mereo BioPharma
- Meridian Medical Technologies
- Merrimack Pharmaceuticals
- Mersana Therapeutics
- Merus
- Merz Pharma
- Millennium Pharmaceuticals
- MiNA Therapeutics
- miRagen Therapeutics
- Mitsubishi Tanabe Pharma
- Moderna Therapeutics
- Molecular Partners
- Molecular Templates
- MolMed
- MorphoSys
- Morphotek
- MTD Micro Molding
- Mylan
- NantBioScience
- Naurex
- Navidea Biopharmaceuticals
- Neogenix Oncology
- Neon Therapeutics
- NeuroDerm
- Nordic Bioscience
- Northern Biologics
- Novartis Pharmaceuticals
- Novimmune
- NOVO Engineering
- Novo Nordisk
- OBI Pharma
- Octapharma
- Omeros
- Oncology Venture
- OncoMed Pharmaceuticals
- OncoPep
- Oncopeptides
- Oncternal Therapeutics
- Oncurious
- Opthea
- Optimer Pharmaceuticals
- OSE Immunotherapeutics
- Otsuka Pharmaceutical
- Paion UK
- Pfizer
- PharmaJet
- PharmaMar
- PharmaSens
- PhaseBio Pharmaceuticals
- Phillips-Medisize
- Philogen
- Phosplatin Therapeutics
- Pierre Fabre
- Pique Therapeutics
- Polaris Group
- Polyphor
- Prescient Therapeutics
- Prestige BioPharma
- Promedior
- Prometheus Laboratories
- Protalix Biotherapeutics
- Proven Process Medical Devices
- Quest PharmaTech
- Quintessence Biosciences
- R-Pharm
- Ratio Drug Delivery
- RAUMEDIC
- Recro Pharma
- Regeneron Pharmaceuticals
- REMD Biotherapeutics
- Resolve Therapeutics
- rEVO Biologics
- Rhythm Pharmaceuticals
- Roche
- Roehr pharmaceuticals
- Sagentia
- Samsung Bioepis
- Sandoz
- Sanofi
- Santarus
- Savient Pharmaceuticals
- scPharmaceuticals
- Seattle Genetics
- Selecta Biosciences
- Selexys Pharmaceuticals
- Sensile Medical
- Serina Therapeutics
- Shire
- SMC Global
- Smiths Medical
- Sonceboz
- SOOIL
- SteadyMed Therapeutics
- Stealth BioTherapeutics
- Stemline Therapeutics
- Stevanato Group
- Subcuject
- Sumitomo Dainippon Pharma
- Sunovion Pharmaceuticals
- SymBio Pharmaceuticals
- Symphogen
- Synectics
- Synermore Biologics
- Syntimmune
- Syros Pharmaceuticals
- TaiMed Biologics
- Taiwan Liposome Company
- Takeda Pharmaceutical
- Tandem Diabetes Care
- Tanvex BioPharma
- Tarveda Therapeutics
- Teva Pharmaceutical
- TG Therapeutics
- Tolero Pharmaceuticals
- TRACON Pharmaceuticals
- Translational Sciences
- Turnstone Biologics
- United BioPharma
- Vaccinex
- Vaccinogen
- Valtronic
- vasopharm BIOTECH
- Verily Life Sciences
- Vetter Pharma
- ViCentra
- Viela Bio
- ViiV Healthcare
- Visterra
- Vitaeris
- Vivozon
- Weibel CDS
- West Pharmaceutical Services
- Wockhardt
- Xbiotech
- Xencor
- XOMA
- Ypsomed
- Zafgen
- Zollner
For more information about this report visit https://www.researchandmarkets.com/research/dg9pwq/global_large?w=5
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Related Links
http://www.researchandmarkets.com
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article